Eli Lilly And Company
lobbying client · lobbying firm
Eli Lilly And Company's federal footprint — reported lobbying spend and, where matched, federal money received. Figures are as reported to the U.S. Senate (LDA) and USAspending.
Reported country: 🇺🇸 United States
Lobbying over time
| FY | Lobbying spend (as client) | Lobbying billed / handled (as firm) |
|---|---|---|
| 2022 | $8,846,850 | $6,806,850 |
| 2023 | $11,741,360 | $9,471,360 |
| 2024 | $13,860,000 | $11,880,000 |
| 2025 | $25,325,000 | $22,695,000 |
Two figures: what Eli Lilly And Company reported spending on its own lobbying (as a client) and what it billed or handled for the clients it represents (as a firm — revenue, not its own spend). For a self-filer these overlap.
Firms hired
- Tiber Creek Health Strategies, INC. $1,270,000 · 16 filings
- Brownstein Hyatt Farber Schreck, LLP $1,180,000 · 16 filings
- Tarplin, Downs & Young, LLC $1,020,000 · 17 filings
- Ferox Strategies $910,000 · 16 filings
- Venn Strategies $800,000 · 16 filings
- Todd Strategy Group $800,000 · 11 filings
- The Simmons & Russell Group, LLC $720,000 · 12 filings
- Thorn Run Partners $720,000 · 9 filings
- Monument Advocacy $680,000 · 17 filings
- Checkmate Government Relations $400,000 · 4 filings
Registrants that filed lobbying on behalf of Eli Lilly And Company.
Clients represented
Self-filed — Eli Lilly And Company registers and lobbies on its own behalf, with no separate outside clients.
Issues
| Issue area | Lobbied | Worked |
|---|---|---|
| Health Issues | 104 | 24 |
| Medicare/Medicaid | 78 | 24 |
| Pharmacy | 71 | 24 |
| Trade (domestic/foreign) | 51 | 24 |
| Copyright/Patent/Trademark | 32 | 24 |
| Taxation/Internal Revenue Code | 30 | 24 |
| Consumer Issues/Safety/Products | 24 | 24 |
| Budget/Appropriations | 18 | — |
| Foreign Relations | 17 | — |
Issue areas across Eli Lilly And Company's filings, by activity count — as the client (Lobbied) and as the registrant/firm (Worked). Linked areas open the CivicGate issue page.
What they lobbied on
Reported activity from Senate LDA
-
FY2025 Trade (domestic/foreign) self-filed
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
-
FY2025 Health Issues self-filed
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
-
FY2025 Medicare/Medicaid self-filed
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
-
FY2025 Consumer Issues/Safety/Products self-filed
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
-
FY2025 Copyright/Patent/Trademark self-filed
Pharmaceutical intellectual property issues
-
FY2025 Taxation/Internal Revenue Code self-filed
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
-
FY2025 Pharmacy self-filed
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
-
FY2025 Trade (domestic/foreign) self-filed
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Show 52 more activities
-
FY2025 Health Issues self-filed
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
-
FY2025 Medicare/Medicaid self-filed
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
-
FY2025 Consumer Issues/Safety/Products self-filed
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
-
FY2025 Copyright/Patent/Trademark self-filed
Pharmaceutical intellectual property issues
-
FY2025 Taxation/Internal Revenue Code self-filed
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
-
FY2025 Pharmacy self-filed
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
-
FY2025 Health Issues as client
There is no specific bill filed. Engagement relates to issues on healthcare and trade.
-
FY2025 Trade (domestic/foreign) as client
There is no specific bill filed. Engagement relates to issues on healthcare and trade.
-
FY2025 Health Issues as client
Alzheimer's Disease. Anti Obesity Medication.
-
FY2025 Medicare/Medicaid as client
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.
-
FY2025 Trade (domestic/foreign) self-filed
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
-
FY2025 Health Issues self-filed
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
-
FY2025 Medicare/Medicaid self-filed
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
-
FY2025 Consumer Issues/Safety/Products self-filed
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
-
FY2025 Copyright/Patent/Trademark self-filed
Pharmaceutical intellectual property issues
-
FY2025 Taxation/Internal Revenue Code self-filed
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
-
FY2025 Pharmacy self-filed
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
-
FY2025 Medicare/Medicaid as client
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity.
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs
-
FY2025 Health Issues as client
Issues related to biotechnology legislation Diagnostic tests clinical trial issues issues related to supply chain
-
FY2025 Medicare/Medicaid as client
Issues related to treatments for Alzheimers therapeutics.
-
FY2025 Pharmacy as client
Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
-
FY2025 Health Issues as client
Issues related to healthcare
-
FY2025 Trade (domestic/foreign) as client
Issues related to trade
-
FY2025 Trade (domestic/foreign) as client
Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.
-
FY2025 Foreign Relations as client
Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.
-
FY2025 Medicare/Medicaid as client
Issues related to treatments for Alzheimers therapeutics.
-
FY2025 Medicare/Medicaid as client
Issues related to treatments for Alzheimers therapeutics.
-
FY2025 Pharmacy as client
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
-
FY2025 Health Issues as client
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
-
FY2025 Health Issues as client
There is no specific bill filed. Engagement relates to issues on healthcare and trade.
-
FY2025 Trade (domestic/foreign) as client
There is no specific bill filed. Engagement relates to issues on healthcare and trade.
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act
-
FY2025 Health Issues as client
Issues related to biotechnology legislation Diagnostic tests clinical trial issues issues related to supply chain
-
FY2025 Health Issues as client
Issues related to healthcare and trade.
-
FY2025 Medicare/Medicaid as client
Issues related to healthcare and trade.
-
FY2025 Trade (domestic/foreign) as client
Issues related to healthcare and trade.
-
FY2025 Pharmacy as client
Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity.
-
FY2025 Foreign Relations as client
Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.
-
FY2025 Trade (domestic/foreign) as client
Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.
-
FY2025 Health Issues as client
Issues related to healthcare
-
FY2025 Trade (domestic/foreign) as client
Issues related to trade
-
FY2025 Health Issues self-filed
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
-
FY2025 Medicare/Medicaid self-filed
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
-
FY2025 Consumer Issues/Safety/Products self-filed
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
-
FY2025 Copyright/Patent/Trademark self-filed
Pharmaceutical intellectual property issues
-
FY2025 Taxation/Internal Revenue Code self-filed
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
-
FY2025 Pharmacy self-filed
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
-
FY2025 Trade (domestic/foreign) self-filed
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
The specific issues and bills Eli Lilly And Company reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.